Health Technology, Healthcare Analytics
businesswire | July 28, 2023
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q2 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive resource on new, pending and projected Specialty and Rare Disease drug launches, and cell and gene therapies, biosimilars and generics. This complimentary, valuable source of industry information supports the specialty drug market needs of stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that are making an impact for millions of individuals living with or affected by rare disease or complex chronic conditions.
“As an industry-leading, global healthcare and specialty pharmacy solutions organization, my team researched, annotated and compiled these critically important updates, timely information, statistics and facts to support our clients and partners and other industry stakeholders,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth.
Dea Belazi, president & CEO, AscellaHealth, adds, “We are proud to empower all market stakeholders with key data and insights that guide the industry. The dedicated work of pharmaceutical manufacturers to launch innovative therapies complemented by the efforts of payers and providers to ensure affordability and treatment availability are so commendable.”
AscellaHealth provides end-to-end, customized solutions to all industry stakeholders, namely patients, life sciences manufacturers, payers and providers to improve medication access, optimize clinical outcomes and enhance the patient journey. Services include:
Pre-Commercialization & Market Access
Exclusive Distribution, Wholesale, and 3PL Services
International Specialty Pharmacy Fulfillment including Limited Distribution Drugs
Comprehensive HUB and Patient Support Services
Custom Compliance and Persistency Programs
Streamlined Prior Authorizations
Technology-based Patient Engagement
Integrated Copay and Financial Assistance Programs
Real-time Rx Data and Analytics
Specialty Pharmacy & Medical Benefit Management
About AscellaHealth LLC
AscellaHealth, a global Healthcare & Specialty Pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, and a NASP Strategic Channel Partner of the Year award winner, AscellaHealth’s best-in-class, patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes, and improve quality of life for this patient population.
businesswire | August 17, 2023
Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a strategic partnership that will enable more efficient clinical trials.
As part of the agreement, Verily will integrate its clinical trial management software (CTMS) platform, SignalPath, across practices in the OneOncology Research Network, OneR. SignalPath will enable sites to improve their systems infrastructure, streamline regulatory processes, and enhance collaboration with sponsors.
“Clinical trial research is core to high-quality cancer care programs,” said Dr. Davey Daniel, Chief Medical Officer, OneOncology. “By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity.”
SignalPath is the only CTMS that uses next-generation protocol digitization technology to configure and systematize study protocol workflows within the platform, saving site staff time and effort. It’s designed to improve the costs, complexities, and time associated with running clinical studies while optimizing for quality and time with patients.
“Verily and OneOncology are both committed to transforming the experience for oncology practices participating in research with the latest data and technology,” said Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath. “SignalPath delivers on that vision, easing the workflow for oncologists and their staff, so they can focus on delivering the best possible care.”
This partnership aims to expand research opportunities across community oncology centers, offering the potential to increase access and participation in clinical trials for new cancer treatments. There are over 1,300 anticancer drugs in the development pipeline, but the participation rate in trials among adult cancer patients in the U.S. is only 6%.
OneOncology will continue to partner with Verily as it further develops connected solutions across its research and care product offerings, including an oncology-focused longitudinal registry to advance cancer research.
Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable.
OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer. Our goal is to enable community oncology practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports its platform of community oncology practices through group purchasing, operational optimization, practice growth, and clinical innovation. The partnership’s 960 cancer care providers care for approximately 528,000 patients at more than 300 sites of care nationwide.
Digital Healthcare, Healthcare Analytics
Businesswire | June 27, 2023
Portable Medical Equipment (PME) such as IV pumps, workstations on wheels (WOWs), and vitals machines can carry and transfer dangerous pathogens between rooms and patients within healthcare facilities because the equipment is often used and rolled between multiple patient rooms. Recognizing the importance of being able to track and report disinfection, Xenex Disinfection Services today announced TrackMate™, a patented device developed by hospitals for hospitals that provides automated tracking of disinfection/cleaning events for PME and hospital rooms. It’s the world’s first automated tracking system and solution for The Joint Commission standard IC 02.02.01 EP1, which focuses on the disinfection of PME.
TrackMate is a small, easy-to-use device that attaches to PME and registers each disinfection\cleaning event stores the data in a secure portal, and provides the data that can be used for compliance and The Joint Commission reporting.
Peer-reviewed studies demonstrated that twice as many PME disinfection events occurred when TrackMate was deployed and 100% of disinfection events were tracked and reported for compliance. TrackMate replaces low tech and often labor-intensive monitoring solutions currently being used in healthcare facilities, such as equipment tags, clipboards and paper checklists, and plastic bags placed over IV poles. It eliminates the need for the manual collection of disinfection event data for Joint Commission compliance reporting.
In addition to tracking disinfection events for PME and rooms, TrackMate can be used anywhere there is a need for tracking disinfection/cleaning, logging of cleaning activity, or automated and remote monitoring of cleaning activity. For example, tracking the cleaning of surfaces in patient rooms, emergency and waiting rooms, nurse stations, kitchens, microbiology laboratories and mannequins in simulation centers.
“Healthcare workers can’t look at an IV pole and know when it was last disinfected, which is why TrackMate is such a game changer. For the first time, disinfection/cleaning event status is being delivered to the user at the point of care. Nurses can quickly look at TrackMate and see when the last disinfection/cleaning event occurred. The CDC has stated that Candida auris is commonly spread via PME – so it’s incredibly important to know when the PME was last cleaned. Infection preventionists and hospital compliance personnel are going to be very excited to learn that we have a solution to IC 02.02.01,” said Dr. Mark “Tuck” Stibich, co-founder and Chief Scientific Officer of Xenex.
TrackMate was invented by Dr. Chetan Jinadatha, Chief of the Infectious Diseases Division at the Central Texas Veterans Health Care System and Clinical Professor, School of Medicine, Texas A&M University. Commercialization of TrackMate is supported by the VA Technology Transfer Program, which facilitates the commercialization of VA inventions to benefit Veterans and the American public. Funding from the National Institutes of Health (NIH) and Central Texas Veterans Healthcare System supported scientific evaluation of the technology.
TrackMate is a small (2”x5”) device that attaches to PME or can be placed in a room. It senses moisture (wipes) or UV light irradiation, collects all of the disinfection/cleaning events and keeps a log locally and online. Events are transmitted once a day through cellular signal to an online database. Supervisors can log in and retrieve the cleaning log for improving cleaning practices or validate compliance with policy. Battery life on each device is 3 years.
About Xenex Disinfection Services
Xenex is a world leader in innovative UV technology-based disinfection strategies and solutions. Xenex's mission is to enable its partners to save lives and reduce suffering by destroying the deadly microorganisms that can cause infections. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures.